Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results

Seres Therapeutics (NASDAQ:MCRB) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.63), FiscalAI reports. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%. The company had revenue of $0.59 million for the quarter, compared to analyst estimates of $6.35 million.

Seres Therapeutics Stock Down 2.6%

Shares of MCRB stock traded down $0.05 during trading on Wednesday, reaching $1.91. 56,330 shares of the company’s stock were exchanged, compared to its average volume of 70,897. Seres Therapeutics has a twelve month low of $1.68 and a twelve month high of $29.98. The firm’s fifty day moving average price is $3.51 and its 200-day moving average price is $7.05. The stock has a market capitalization of $19.20 million, a PE ratio of -0.78 and a beta of 0.44.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MCRB. Weiss Ratings downgraded Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.